ArticleThe World Allergy Organization journal2026
Efficacy predictions for omalizumab treatment based on basophil CD203c expression in patients with allergic rhinitis by basophil activation test -- a real-life, pilot study.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Basophils are key targets in allergic diseases. Omalizumab blocks IgE binding to FcεRI on basophils, reducing allergic responses. The basophil activation test aids allergy diagnosis, but their role in allergic rhinitis (AR) remains unclear. We assessed omalizumab's impact on basophil reactivity and its clinical associations in moderate-to-severe AR. Objective: This study aimed to determine the predictive value of CD203c and CD63 as basophil activation markers for clinical response to omalizumab in patients with moderate-to-severe allergic rhinitis. Methods: We collected and analyzed clinical symptoms and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores of 27 patients with moderate-to-severe AR who were treated with omalizumab for more than 12 weeks. Patients were divided into a non-basopenic group (OMA-AR/NB) and a basopenic group (OMA-AR/B) based on peripheral blood basophil counts (basopenic: <8000 cells/mL). FcεRI, CD63, and CD203c expression on blood basophils induced by stimulant were measured at baseline and at 12 weeks after omalizumab treatment using flow cytometry. Results: The RQLQ score in OMA-AR/NB decreased from 33.0 ± 11.0 at baseline to 5.2 ± 4.2 at 12 weeks, while in OMA-AR/B, the score decreased from 33.8 ± 7.6 at baseline to 19.4 ± 5.9 at 12 weeks. Additionally, the basophil activation assay yielded the best classification accuracy (73.97% sensitivity, 88.89% specificity, cut-off value: 8.0%) for %CD203c+ in patients with AR. Conclusion: During omalizumab treatment in patients with AR, CD203c was a more suitable marker for the basophil activation test (BAT). Furthermore, %CD203c
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.